Second-line protease inhibitor-based HAART after failing non-nucleoside reverse transcriptase inhibitorbased regimens in Asian HIV-infected children

• المؤلفون الرئيسيون: Torsak Bunupuradah, Thanyawee Puthanakit, Paul Fahey, Azar Kariminia, Nik K.N. Yusoff, Truong H. Khanh, Annette H. Sohn, Kulkanya Chokephaibulkit, Pagakrong Lumbiganon, Rawiwan Hansudewechakul, Kamarul Razali, Nia Kurniati, Bui V. Huy, Tavitiya Sudjaritruk, Nagalingeswaran Kumarasamy, Siew M. Fong, Vonthanak Saphonn, Jintanat Ananworanich
• التنسيق: دورية
• منشور في: 2018
• الوصول للمادة أونلاين: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84885343575&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/47575

Background: The World Health Organization (WHO) recommends boosted protease inhibitor (bPI)-based HAART after failing non-nucleoside reverse transcriptase inhibitor (NNRTI) treatment. We examined outcomes of this regimen in Asian HIV-infected children. Methods: Children from five Asian countries in...